A lexicon for psychedelic research and treatment

The field of psychedelic research lacks standardized terminology for clinical development, dosing, safety monitoring, and regulatory classification. A comprehensive framework is proposed that classifies psychedelics by pharmacology (serotonergic, glutamatergic, kappaergic, GABAergic, and atypical), introduces dose-dependent categories (microdose, minidose, mididose, macrodose), and standardizes terms like “short-acting” with specific pharmacokinetic parameters. Safety considerations include cardiovascular and psychological effects, with risk mitigation protocols for higher-risk compounds like ibogaine. A three-phase treatment model—preparation, dosing, and integration—is recommended as a minimum standard. The lack of comparative research on psychotherapy modalities is identified as a critical gap.

Study at a glance

Abstract

Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here, we present a comprehensive framework for psychedelic nomenclature based on pharmacology, subjective effects, dosing, and therapeutic use. A pharmacological classification system is described, encompassing serotonergic, glutamatergic, kappaergic, GABAergic, and atypical psychedelics. Dose-dependent categories—microdose, minidose, mididose, and macrodose—are introduced to standardize the description of dosing levels and intended subjective effects. We also standardize vague terms like “short-acting” or “long-acting” with specific pharmacokinetic parameters, including route, onset, and duration of action. Safety considerations are also explored, particularly cardiovascular and psychological effects, and we discuss the need for risk mitigation protocols in higher-risk compounds like ibogaine. The evolving role of psychotherapy in psychedelic treatment is also examined, proposing terminology to distinguish between “psychedelic therapy” and varying levels of psychological support. A three-phase treatment model—preparation, dosing, and integration—is recommended as a minimum standard for safe and effective care. The lack of comparative research on psychotherapy modalities in psychedelic therapy is identified as a critical gap. Ultimately, a standardized lexicon and clinical framework will support clearer communication, improved trial design, and more equitable access as psychedelic therapies move toward widespread clinical use.